Image: Bigstock

BioLife Solutions, Inc. (BLFS Quick Quote BLFS - Free Report) came out with a quarterly loss of $0.06 per share in line with the Zacks Consensus Estimate. This compares to break-even earnings per share a year ago. These figures are adjusted for non-recurring items.

A quarter ago, it was expected that this company would post a loss of $0.04 per share when it actually produced a loss of $0.04, delivering no surprise.

Over the last four quarters, the company has surpassed consensus EPS estimates just once.

BioLife Solutions, Inc.Which belongs to the Zacks Medical - Products industry, posted revenues of $14.73 million for the quarter ended December 2020, surpassing the Zacks Consensus Estimate by 9.67%. This compares to year-ago revenues of $8.3 million. The company has topped consensus revenue estimates four times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

BioLife Solutions, Inc. Shares have lost about 2.8% since the beginning of the year versus the S&P 500's gain of 4.2%.

What's Next for BioLife Solutions, Inc.

While BioLife Solutions, Inc. Has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for BioLife Solutions, Inc. Was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future.